Review Compares Analgesic Interventions After Shoulder Surgery
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- The average pain trajectories after shoulder surgery vary with different analgesic interventions, according to research presented at the 49th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, held from March 21 to 23 in San Diego.
Sheila Gokul, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined average pain trajectories with different analgesic interventions for 48 hours after shoulder surgery in a systematic review of randomized controlled trials and cohort studies assessing pain scores according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Data were included from 74 studies, with 4,676 patients. The researchers identified three main treatment groups: continuous nerve block (CNB), single shot nerve block (SSNB), and conventional analgesia (CA). At 12 hours postoperatively after all shoulder surgeries, pain scores differed significantly in the presence of CNB, SSNB, and CA (mean, 1.04, 2.39, and 4.52, respectively). At both 24 and 48 hours, patients with CNB reported very low pain scores on average (1.84 and 1.51, respectively). On direct comparison of CNB and SSNB, there was no significant difference observed between the groups in immediate postoperative pain (1.55 and 1.49); at 12, 24, and 48 hours, the CNB group had significantly lower mean pain scores (1.04 versus 2.39, 1.84 versus 3.05, and 1.51 versus 2.62, respectively).
"In this systematic summative review, we observed the average pain trajectories after shoulder surgery and found that pain was significantly different at most time points in the 48 hours after surgery between conventional therapy, SSNB, and CNB," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
Small Number of Procedures Account for Large Number of Opioid Prescriptions
FRIDAY, June 28, 2024 -- A small number of surgical procedures, including orthopedic procedures and cesarean delivery, account for a large proportion of opioid prescriptions...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.